[Parietal theta rhythms in carbamazepine therapy of children with epilepsy]
Insights
Parietal theta rhythm (PT) in children with epilepsy is linked to poorer outcomes with carbamazepine (CBM) therapy. This EEG pattern may predict a reduced response to CBM treatment.
Area of Science:
- Neuroscience
- Clinical Neurology
- Epilepsy Research
Context:
- Epilepsy is a neurological disorder characterized by recurrent seizures.
- Parietal theta rhythm (PT) is an EEG pattern sometimes associated with a predisposition to epilepsy.
- Carbamazepine (CBM) is a common antiepileptic drug used in treating epilepsy.
Purpose:
- To evaluate the efficacy of carbamazepine (CBM) therapy in children with epilepsy, comparing those with and without parietal theta rhythm (PT).
- To investigate the prognostic value of PT in predicting CBM treatment response and disease course.
Summary:
- A retrospective study examined 119 children with epilepsy, divided into groups with (n=63) and without (n=56) PT, excluding those with pre-existing generalized spike-and-wave activity (SWA).
- Results showed significantly worse CBM response in the PT group (22% marked effect, 65% mild/absent effect, 13% worsening) compared to the non-PT group (75% good effect, 25% no effect).
- Correlations were found between SWA appearance and inadequate CBM action, and between EEG improvement and favorable prognosis.
Impact:
- Carbamazepine efficacy is notably reduced in pediatric epilepsy patients presenting with parietal theta rhythm.
- Parietal theta rhythm may serve as a predictive factor for the development of generalized spike-and-wave activity during CBM therapy.
- Findings suggest PT is a significant factor influencing treatment outcomes in pediatric epilepsy, necessitating tailored therapeutic strategies.
Unlabelled:
Regional bioelectrical activity changes presenting as prolonged or periodic inhibition at the central parietal leads in theta rhythm (PT) are regarded in some studies as congenital predisposition to epilepsy. The study estimates a carbamazepine (CBM) therapy efficacy in children with epilepsy with- or without PT. To study the prognosis in CBM therapy, 119 patients, 63 with PT (group 1) and 56--without PT (group 2) have been retrospectively examined. Patients with the presence of generalized spike-and-wave activity (SWA) before CBM treatment have been excluded from the study. Despite the insignificant between-group differences of clinical and EEG-data before the therapy beginning, the CBM response was much worse in the group 1: a marked effect was found in 14 (22%) patients, in 41 (65%) the effect was mild or absent at all, and in 8 (13%) a disease course worsening was detected. In group 2 a good effect was in 42 (75%) patients, no effect was detected in 14 (25%) patients and none of the patients was worse. Correlations between SWA appearance and inadequate CBM action, as well as between improvement/worsening absence of EEG and favorable prognosis during therapy have been found.
Conclusions:
Carbamazepine efficacy in the children with epilepsy is significantly lower in the presence of parietal theta rhythm. PT is likely to be a liability factor for SWA appearance during CBM therapy.
More Related Videos
Related Concept Videos
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:23Brain Waves